SHREYA GOEL

We are a multi-disciplinary group seeking to illuminate drug and disease mechanisms and pharmaceutical delivery through the use of advanced imaging techniques, molecular therapeutics, and combining the two into theranostics.

We are particularly interested in developing quantitative radiological biomarkers to interrogate dysregulated vasculature, hypoxia, and stroma; biological processes that dictate disease progression, treatment response and resistance, in several physiological and pathological conditions. Noninvasive and longitudinal assessments of these biomarkers can provide high impact by 1) differentiating responders from non-responders, before or soon after treatment has started, and 2) enabling biology-guided modulation of the disease microenvironment to convert non-responders to responders, for a truly personalized approach. 

We are also interested in applying multiscale imaging technologies such as positron emission tomography, computer tomography, optical and optoacoustic imaging, and high-resolution microscopy, to quantitatively visualize the pharmacokinetics of biomolecular and nanomaterials-based therapies. Precise evaluations of pharmacokinetic and pharmacodynamic behavior of established and investigational therapies can guide rational reverse-engineering of effective and innovative next-generation therapies, which are poised to have an outstanding impact on basic and translational pharmaceutical and biomedical sciences.